官方服务：
资源简介：
UGE, urinary glucose excretion; PBO, placebo; CANA, canagliflozin; QD, once daily; BID, twice daily.
应用场景：
创建时间：
2016-02-23
相关数据集
Dataset from Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
NIAID Data Ecosystem10
DataSheet_1_Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.docx
ObjectsImigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function in Chine
NIAID Data Ecosystem10
Plasma and tissue measurements from hGCGR HFD/STZ mice treated for 6 weeks with 10 mg/kg GRA1, des-fluoro-sitagliptin (des-F-sita), or GRA1 and des-fluoro-sitagliptin in combination.
aFasting blood glucose and HbA1c were measured after 5 weeks of treatment; all other measurements were made in terminal plasma and necropsy tissue. The data are means ± SEM; *p
Figshare2015-12-02 更新00
Table_1_Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.docx
ObjectiveThe study aims to investigate the effect of metformin on Hepatocellular carcinoma (HCC) patients with type 2 diabetes mellitus (T2DM) who received transarterial chemoembolization (TACE) for t
NIAID Data Ecosystem10
Dataset from A 52-week Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Empagliflozin Once Daily, as an add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellit
NIAID Data Ecosystem00
